Upgrade to SI Premium - Free Trial

Kura Oncology (KURA) Reiterated at Market Outperform by Citizens on FIT-001 Data Preview

May 28, 2026 5:21 AM
Citizens analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments